早期上皮性卵巢癌盆腔及腹主动脉旁淋巴结清扫的治疗作用
多中心回顾性队列研究纳入639例明显早期上皮性卵巢癌患者,比较全面淋巴结清扫(≥20枚)与取样/不清扫的预后。全面清扫组5年无病生存率79.7%,独立改善DFS(HR 0.52,95%CI 0.37-0.73),但未改善总生存,且术后严重并发症更多、化疗开始更晚。
要点
- 全面淋巴结清扫独立改善DFS(HR 0.52),但未改善OS。
- 清扫组严重术后并发症更多、化疗开始时间更长。
- 需结合肿瘤生物学识别真正从清扫获益的患者。
核心结论
- 盆腔及腹主动脉旁淋巴结清扫改善早期上皮性卵巢癌DFS但不影响OS,代价是术后并发症增加和化疗延迟。
研究设计与样本
- 多中心回顾性队列研究,1985年5月至2016年12月,纳入639例FIGO IA-IIIA1期明显早期上皮性卵巢癌患者。
- 比较全面双侧盆腔及腹主动脉旁淋巴结清扫(≥20枚)与淋巴结取样或不清扫。
- 排除CT示大块淋巴结及未完成腹腔内全面分期者,仅纳入至少3周期铂类辅助化疗患者。
主要发现
- 全面清扫组360例(56.3%),取样组150例(23.5%),不清扫组129例(20.2%)。
- 中位随访63个月(范围5-342),5年DFS分别为79.7%、76.5%、68.3%(p=0.006)。
- 5年OS分别为92.3%、94.5%、89.8%(p=0.165)。
- 淋巴结清扫是DFS改善的独立因素,HR 0.52(95%CI 0.37-0.73)(p<0.001)。
- 全面清扫组更年轻(p<0.001)、严重术后并发症更多(p=0.008)、化疗开始时间更长(p=0.034),术中并发症无差异。
临床怎么用
- 对明显早期上皮性卵巢癌,全面淋巴结清扫可改善DFS但需权衡术后并发症和化疗延迟。
- 不应仅以OS获益为目的常规推荐全面淋巴结清扫,需个体化选择患者。
局限性
- 回顾性队列设计可能存在选择偏倚。
- 仅纳入接受至少3周期铂类化疗的患者,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The therapeutic role of pelvic and para-aortic lymphadenectomy in surgical staging of apparent early-stage epithelial ovarian cancer (eEOC) is still under debate. The aim of this study was to evaluate the potential therapeutic role of systematic lymphadenectomy in patients with eEOC. METHODS: Multi-center retrospective cohort study, comparing women with apparent eEOC who underwent comprehensive bilateral pelvic and para-aortic lymphadenectomy (defined as ≥20 lymph nodes) versus patients receiving no lymphadenectomy or lymph node sampling, from 05/1985 to 12/2016. Patients with bulky nodes at CT-scan and those without complete intra-peritoneal surgical staging were excluded. Only patients who received at least 3 cycles of platinum-based adjuvant chemotherapy were included. RESULTS: Out of 2559 patients with FIGO stage IA-IIIA1 ovarian cancer, 639 (25.0%) met inclusion criteria. 360 (56.3%) underwent comprehensive lymphadenectomy, 150 (23.5%) lymph node sampling and 129 (20.2%) no lymphadenectomy. Patients who underwent comprehensive lymphadenectomy were younger (p < 0.001), experienced a higher number of severe post-operative complications (p = 0.008) and had a longer time to start chemotherapy (p = 0.034). There was no difference in intra-operative complications. Median follow-up was 63 months (range, 5-342). The 5-year disease-free survival (DFS) was 79.7% vs. 76.5% vs. 68.3% (p = 0.006), and 5-year overall survival (OS) was 92.3% vs. 94.5% vs. 89.8% (p = 0.165) in women who received comprehensive lymphadenectomy vs. lymph node sampling vs. no lymphadenectomy, respectively. Lymphadenectomy represented an independent factor for DFS improvement, HR 0.52 (95%CI 0.37-0.73) (p < 0.001). CONCLUSION: Pelvic and para-aortic lymphadenectomy in surgical staging of eEOC improves DFS for the price of increasing post-operative complications and time to chemotherapy but does not affect OS. Better understanding of tumor biology may help to identify those patients in whom lymphadenectomy should still play a role.
引用
- Bizzarri N, du Bois A, Fruscio R, et al. Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer? Gynecol Oncol. 2020. PMID: 33168305. doi:10.1016/j.ygyno.2020.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。